BioSpace News Archive

Newron Pharmaceuticals S.p.A. presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine.

Incyte Corporation announced that its Board of Directors approved a share repurchase authorization of $2.0 billion.

Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms, announced the closing of an oversubscribed $95 million Series C financing.

Moderna, Inc., announced its participation in the following upcoming investor conferences:

Aurora Spine Corporation, a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced it has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results that ended March 31, 2024.

Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update.

Avanos Medical, Inc. announced that Sigfrido Delgado has been appointed senior vice president, integrated supply chain.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close.

Avalo Therapeutics, Inc., announced business updates and financial results for the first quarter of 2024.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update.